Renewing health
Upcoming SlideShare
Loading in...5

Renewing health






Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Renewing health Renewing health Presentation Transcript

      • RENEWING HEALTH aims at implementing large-scale real-life test beds for the validation and subsequent evaluation of innovative telemedicine services using a patient-centred approach and a common rigorous assement methodology
      • Involving 7800 patients
      • Start 2010-02-01-2012-08-31
    • Clinical objectives
      • The project improves the quality of life of patients suffering from diabetes, chronic obstructive pulmonary or cardiovascular diseases.
    • Patient/user perspective objectives
      • The project will provide coherent clinical services through ICT that take into consideration patients’ and professional users’ needs, capabilities, risks and benefits.
    • Economic objectives
      • The project implements a new healthcare model that is expected to reduce the cost of chronic patients care to the society
    • Organisational objectives -
      • The project intends to create an organisational model for telemedicine services that ensures a safe, clear and efficient pathway for patients
    • 9 regions in Europe
      • Norrbotten (Sweden)
      • Northern Norway (Norway)
      • South Karelia (Finland)
      • Carinthia (Austria)
      • Berlin (Germany)
      • Thessaly (Greece)
      • Region of Southern Denmark
      • Veneto (Italy)
      • Catalonia (Spain)
    • Clusters
      • Regions are divided in 7 clusters based on similarities in interventions and chronic conditions.
      • The project in Norrbotten is in two cluster; diabetes and cardivascular diseases
    • The project in Norrbotten The Diabetes Epidemic and tele-enabled integrated care
      • The prevalence of diabetes type II is rising. In Norrbotten the prevalence is 7% of the population.
      • Diabetes II is treated mainly by life-style interventions in diet, smoking and physical activity, supported by medical treatment.
      • The aim of the treatment is to lower blood glucose, lipids, blood pressure and weight.
    • The project in Norrbotten The Diabetes Epidemic and tele-enabled integrated care
      • Self-management support is established as an evidence-based intervention for diabetes and it has been concluded that self-management support is effective
      • To improve patients HbA1c and their health-related quality of life by providing them with technology
      • Trial start and end: 01.02.2011 – 31.07.2012
    • The intervention
      • Participants use their own PC or receive an Android-based tablet PCs (ViewSonic ViewPad 7) with a dedicated software that manages the collection and transmission of their diagnostic measurements.
      • An integrated local health application to The National Patient Portal “My health Care Contacts”
    • Study type
      • Randomised parallel group non-blinded trial with an intervention group and a control group (routine care only).
      • Four primary healthcare centres
      • Sample size: 200 / 200
    • Inclusioncritera
      • T2DM diagnosed > 3 months prior to the enrolment
      • HbA1c > 53mmol/mol
      • Age > 18 years
      • Capability of filling questionnaires by their own language
      • Being able to use the devices provided
      • Being cognitively able to participate
      • Absence of severe comorbidity
      • Not pregnant
    • Evaluation
      • The evaluation using as a basis the MAST (Model for Assessment of Telemedicine) assessment model.
      • Primary outcome: Health-related quality of life (measured with SF-36) (beginning and trial end HbA1c (beginning and trial end)
    • Evaluation
      • Secondary outcome:
      • Socio-demographic and clinical baseline characteristics
      • Economical: All costs of the organisation calculated for both intervention and control groups.
      • Patient perception: the WSD questionnaire
    • Thank you for listening Inger Lindberg, assistant professor, RNM, PhD